CDK4 and neoplasm: Of note, Goel et al. (2017) demonstrated that CDK4/6 inhibitors increase anti-tumor immunity by activating tumor antigen presentation and reducing proliferation of Tregs through suppressing DNA methyltransferase 1 activity [36].